Loading
A phase 1 trial of BBI-825 run by Boundless Bio, Inc., terminated.
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications is a phase 1 interventional study registered as NCT06299761 by Boundless Bio, Inc., with 19 participants enrolled, started 2024-03-28. Conditions recorded: Solid Tumor. Interventions recorded: BBI-825.
Shares BBI-825, Boundless Bio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Boundless Bio and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/